Macular Atrophy Progression and 7-Year Vision Outcomes in Subjects From the ANCHOR, MARINA, and HORIZON Studies: the SEVEN-UP Study

• Published in: American journal of ophthalmology Vol. 159; no. 5; pp. 915 - 924.e2
• Main Authors: Bhisitkul, Robert B., Mendes, Thais S., Rofagha, Soraya, Enanoria, Wayne, Boyer, David S., Sadda, SriniVas R., Zhang, Kang
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2015; Elsevier Limited
• Subjects: Age; Aged; Aged, 80 and over; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Confidence intervals; Diabetic retinopathy; Disease Progression; Eyes & eyesight; Female; Fluorescein Angiography; Follow-Up Studies; Geographic Atrophy - diagnosis; Geographic Atrophy - physiopathology; Health Insurance Portability & Accountability Act 1996-US; Humans; Incidence; Intravitreal Injections; Macular degeneration; Male; Medical imaging; Middle Aged; Ophthalmology; Ranibizumab; Retrospective Studies; Studies; Tomography, Optical Coherence; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - physiology; Wet Macular Degeneration - diagnosis; Wet Macular Degeneration - drug therapy; Wet Macular Degeneration - physiopathology; New York; South San Francisco California; California

To assess the incidence and progression of macular atrophy and other key anatomic outcomes over 7 to 8 years in an early cohort of ranibizumab-treated exudative age-related macular degeneration patients. Follow-up analysis of long-term outcomes in a multicenter treatment cohort. Fourteen study sites...